Lecicarbon Felnőtt

Sodium hydrogen carbonate, the active ingredient in Lecicarbon Felnőtt, is a buffering agent presented as a rectal formulation for rectal use. It helps adjust the pH within the rectal cavity. GNH USA supplies Lecicarbon Felnőtt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lecicarbon Felnőtt is used to modify rectal pH, supporting procedures that require a neutral environment.

Rectal alkalinization before endoscopic examination: helps achieve a neutral pH to improve visualization. Rectal preparation for pelvic radiotherapy: buffers acidity to reduce tissue irritation. Management of rectal irritation from acidic exposure: neutralizes excess acid to relieve discomfort.

Common Side Effects: - Mild rectal irritation or burning sensation. - Slight abdominal discomfort or cramping. - Transient flatulence or bloating. - Mild diarrhea or loose stools. - Temporary rectal discharge. - Minor nausea.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) with rash, swelling, or breathing difficulty. - Significant electrolyte imbalance, such as hypernatremia. - Metabolic alkalosis from excessive bicarbonate absorption. - Severe rectal bleeding or ulceration. - Persistent severe abdominal pain. - Unexplained dizziness or fainting.

Before using Lecicarbon Felnőtt, consider the following precautions: - Pregnancy: safety has not been established; use only if clearly needed. - Breastfeeding: caution advised as excretion in milk is unknown. - Renal impairment: monitor electrolyte levels and renal function. - Existing electrolyte disorders: avoid in hypernatremia or severe metabolic alkalosis. - Concurrent alkalinizing agents: risk of over‑correction; assess need. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Lecicarbon Felnőtt may interact with other medicines as follows:

Major Interactions (Avoid): - Systemic sodium bicarbonate: combined use can cause metabolic alkalosis. - Potassium‑sparing diuretics: may increase risk of hyperkalemia. - Calcium carbonate: can precipitate and reduce effectiveness.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor blood pressure and renal function. - NSAIDs: watch for renal impairment. - Other antacids: assess electrolyte balance regularly.